% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Donner:821062,
author = {Donner, L. and Falker, K. and Gremer, L. and Klinker, S.
and Pagani, G. and Ljungberg, L. U. and Lothmann, K. and
Rizzi, F. and Schaller, M. and Gohlke, H. and Willbold, D.
and Grenegard, M. and Elvers, M.},
title = {{P}latelets contribute to amyloid- aggregation in
cerebral vessels through integrin {II}b 3-induced
outside-in signaling and clusterin release},
journal = {Science signaling},
volume = {9},
number = {429},
issn = {1937-9145},
address = {Washington, DC [u.a.]},
publisher = {Assoc.},
reportid = {FZJ-2016-06306},
pages = {ra52 - ra52},
year = {2016},
abstract = {Cerebral amyloid angiopathy (CAA) is a vascular dysfunction
disorder characterized by deposits of amyloid-β (Aβ) in
the walls of cerebral vessels. CAA and Aβ deposition in the
brain parenchyma contribute to dementia and Alzheimer's
disease (AD). We investigated the contribution of platelets,
which accumulate at vascular Aβ deposits, to CAA. We found
that synthetic monomeric Aβ40 bound through its RHDS
(Arg-His-Asp-Ser) sequence to integrin αIIbβ3, which is
the receptor for the extracellular matrix protein
fibrinogen, and stimulated the secretion of adenosine
diphosphate (ADP) and the chaperone protein clusterin from
platelets. Clusterin promoted the formation of fibrillar Aβ
aggregates, and ADP acted through its receptors P2Y1 and
P2Y12 on platelets to enhance integrin αIIbβ3 activation,
further increasing the secretion of clusterin and Aβ40
binding to platelets. Platelets from patients with
Glanzmann's thrombasthenia, a bleeding disorder in which
platelets have little or dysfunctional αIIbβ3, indicated
that the abundance of this integrin dictated Aβ-induced
clusterin release and platelet-induced Aβ aggregation. The
antiplatelet agent clopidogrel, which irreversibly inhibits
P2Y12, inhibited Aβ aggregation in platelet cultures; in
transgenic AD model mice, this drug reduced the amount of
clusterin in the circulation and the incidence of CAA. Our
findings indicate that activated platelets directly
contribute to CAA by promoting the formation of Aβ
aggregates and that Aβ, in turn, activates platelets,
creating a feed-forward loop. Thus, antiplatelet therapy may
alleviate fibril formation in cerebral vessels of AD
patients.},
cin = {ICS-6},
ddc = {500},
cid = {I:(DE-Juel1)ICS-6-20110106},
pnm = {553 - Physical Basis of Diseases (POF3-553)},
pid = {G:(DE-HGF)POF3-553},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000376467800003},
pubmed = {pmid:27221710},
doi = {10.1126/scisignal.aaf6240},
url = {https://juser.fz-juelich.de/record/821062},
}